Monogram Orthopaedics Inc

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Monogram Orthopaedics, Inc. operates as a medical technology company. It intends to produce and market robotic surgical equipment and related software, orthopaedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. The company was founded by Douglas Unis in 2015 and is headquartered in Austin, TX.

510(k) Submission with FDA Accelerated for Early Second Half of 2024 AUSTIN, TX / ACCESSWIRE / May 1, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update related to the regulatory and commercialization path for its mBôs surgical system following its meeting with the U.S. Food and Drug Administration (the "FDA"). On April 19, 2024, Monogram received written feedback from the FDA regarding the Company's Q1 2023 pre-submission request.

Monogram Provides Regulatory Update Following Meeting with FDA

Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs System AUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA. NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures with go-to-market support, expertise, and technology assistance.

Monogram Accepted to NVIDIA Inception Program

Monogram Orthopaedics, Inc. (MGRM) Q4 2023 Earnings Call Transcript

AUSTIN, TX / ACCESSWIRE / March 20, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced management will host a business update conference call on Thursday, March 21, 2024 at 5:00 p.m. Eastern time to discuss its results for the full fiscal year ended December 31, 2023, and will be providing regulatory updates, reviewing ongoing initiatives and technology strategy, and anticipated 2024 milestones.

Monogram Orthopaedics to Host Business Update Conference Call on Thursday, March 21st at 5:00 p.m. Eastern Time

510(k) Submission with FDA On Track for Second Half of 2024 Shipped mBôs Surgical Robot System to First International Customer Introduced mVision Technologies, a Novel Approach to Registration and Tracking Management to Host Business Update Conference Call on Thursday, March 21 at 5:00 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / March 15, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.

Monogram Orthopaedics Reports Full Year 2023 Financial Results

Event features Monogram's mBôs commercial robot alongside panel of orthopaedic surgeons AUSTIN, TX / ACCESSWIRE / February 12, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, hosted a recorded discussion of features of Monogram's mBôs and mVision technologies with a surgeon panel. Monogram's mVision technology is a novel approach to registration and tracking that the company is now working on for integration into the mBôs surgical robotic system in the future.

Monogram Orthopaedics to Present Rescheduled Product Discussion with Surgeon Reaction during AAOS Annual Meeting

AUSTIN, TX / ACCESSWIRE / January 24, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, announced today that management will present at the Canaccord Genuity 2024 Musculoskeletal Conference taking place February 12, 2024, in San Francisco. Ben Sexson, Chief Executive Officer, is scheduled to host a presentation during the conference and will also participate in one-on-one meetings with Chief Financial Officer Noel Knape during the conference.

Monogram Orthopaedics to Present at the Canaccord Genuity Musculoskeletal Conference on February 12, 2024

AUSTIN, TX / ACCESSWIRE / December 14, 2023 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, announced that its live stream product demonstration of features of its commercial robot has been postponed due to management's international travel schedules. The Company will provide a new date for the live stream pending management availability.

Monogram Orthopaedics to Reschedule Robotic Product Demo Live Stream

- Demo will feature Monogram's mBôs commercial robot with teaser - AUSTIN, TX / ACCESSWIRE / November 30, 2023 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, will host a live stream product demonstration of features of its commercial robot on Thursday, December 14, 2023, at 11:00 a.m. Eastern Time.

Monogram Orthopaedics to Host Robotic Product Demo Live Stream on Thursday, December 14, 2023 at 11:00 a.m. Eastern Time

- First Sale to Major Global Distributor Represents Key Revenue Milestone and Paves the Way for Broader Commercialization - AUSTIN, TX / ACCESSWIRE / November 28, 2023 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, has delivered its first surgical robot to one of the world's largest global robotics distributors. "Delivering our first robot and realizing our first commercial revenues validates our technology and represents a pivotal milestone for our strategic roadmap," said Ben Sexson, Chief Executive Officer of Monogram Orthopaedics.

Monogram Orthopaedics Delivers First Surgical Robot

- Presentation Highlights MGRM's Competitive Differentiation and Multi-Stage Growth Strategy - AUSTIN, TX / ACCESSWIRE / October 20, 2023 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced the filing of an 8-K with the U.S. Securities and Exchange Commission ("SEC") that included an updated presentation regarding the business of the company. The presentation highlights the Company's vision, competitive differentiation, multi-stage product strategy, and market opportunities.

Monogram Orthopaedics Files Updated Presentation on Form 8-K

Monogram Orthopaedics, Inc. went public in May 2023 and raised $17.2 million for its autonomous robotic surgical system for knee replacement surgery. The company is still in the development stage and will require significant additional capital to fund its plans. The stock is an ultra-high-risk investment, and my outlook is to Sell.

Monogram Orthopaedics Faces Tough Road Ahead For Surgical Robotics System

Completion of the Development Phase Represents a Key Milestone Toward Product Commercialization AUSTIN, TX / ACCESSWIRE / August 14, 2023 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced the completion of the Development Phase and the start of the Verification Phase for the Company's next-generation autonomous surgical robotic system, a key milestone in Monogram's commercialization journey. The development cycle for medical devices involves several phases to ensure their effective and safe production, including Conceptualization, Feasibility Studies, Design and Development, Verification, Validation, Regulatory Approval and Clinical Evaluation, and Manufacturing and Commercialization.

Monogram Orthopaedics' Next Generation Surgical Robotic System Enters Verification Phase

Moves from R&D to Commercialization AUSTIN, TX / ACCESSWIRE / July 18, 2023 / Monogram Orthopaedics Inc., (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and orthopedic implants, today announced the Company executed a conditional purchase order to initiate a pilot program with a global distributor. Monogram will update its system software to facilitate robotic surgery with the distributor's implants for comprehensive evaluation.

Monogram Orthopaedics Secures First Conditional Purchase Order to Initiate Pilot Program with Global Distributor

AUSTIN, TX / ACCESSWIRE / May 23, 2023 / Monogram Orthopaedics Inc., (NASDAQ:MGRM) ("Monogram" or the "Company") a medical technology company focused on reconstructive joint procedures and orthopedic implants, today announced it has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Monogram management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community.

Monogram Orthopaedics Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

Monogram Orthopaedics (NASDAQ: MGRM ) stock is heading higher on Friday after the company's shares made their public debut on Thursday! The Monogram Orthopaedics IPO saw the company selling 2.4 million shares of MGRM stock at a price of $7.25 each.

Why Is Monogram Orthopaedics (MGRM) Stock Up 61% Today?

Farfetch

Monogram Orthopaedics Inc. MGRM, +62.07% shares surged 278% in premarket trading. The medical technology group began trading on the Nasdaq on Thursday, with the stock ending the first day of trading at $11.75 per share from a $7.25 offer price it settled on late Wednesday.

Monogram Orthopaedics shares rally, Farfetch stock gains and other stocks on the move

Monogram Orthopaedics (NASDAQ: MGRM ) stock is ripping higher on Thursday as it makes its public debut. Trading under MGRM stock, shares are currently up more than 50% from the offering price.

MGRM Stock Alert: 7 Things to Know as Monogram Orthopaedics Starts Trading

Medical Technology Company Ushering in the Future of Joint Reconstruction Will Trade Under Ticker Symbol "MGRM" AUSTIN, TX / ACCESSWIRE / May 18, 2023 / Monogram Orthopedics (NASDAQ:MGRM), a leader in developing patient-optimized, 3D-printed orthopedic implants enabled by robotics with advanced pre-operative imaging, today announced it raised $17,216,147 is pleased to announce that its common stock will begin trading on the NASDAQ today, May 18, 2023, at approximately 11:00 am EST under the ticker symbol "MGRM." Digital Offering, LLC, acted as the lead managing selling agent, along with R.F.

Monogram Orthopaedics Shares Begin Trading Publicly on NASDAQ

Shares to Begin Trading on NASDAQ on May 18, 2023 Under the Ticker Symbol "MGRM" AUSTIN, TX / ACCESSWIRE / May 17, 2023 / Monogram Orthopaedics Inc., a leader in developing patient-optimized, 3D-printed orthopedic implants enabled by robotics with advanced pre-operative imaging, today announced it raised $17,216,147 through the sale of 2,374,641 shares of its Class A Common Stock priced at $7.25 per share. Monogram expects the stock to begin trading on NASDAQ under the ticker symbol "MGRM" on May 18, 2023.

News for Monogram Orthopaedics Inc Stock (MGRM)